Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial
Yasutoshi Kuboki, Marwan Fakih, John H. Strickler, et al.
Nature Medicine (2024) Vol. 30, Iss. 1, pp. 265-270
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
Rona Yaeger, Nataliya V. Uboha, Meredith S. Pelster, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 982-993
Open Access | Times Cited: 28
Combinatorial strategies to target RAS-driven cancers
Naiara Perurena, Lisa Situ, Karen Cichowski
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 316-337
Closed Access | Times Cited: 22
Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver
Javier Ros, Caterina Vaghi, Iosune Baraibar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3304-3304
Open Access | Times Cited: 15
KRAS G12C inhibitor combination therapies: current evidence and challenge
Hirotaka Miyashita, Shumei Kato, David S. Hong
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Signaling pathways in liver cancer: pathogenesis and targeted therapy
Yangtao Xue, Yeling Ruan, Yali Wang, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 10
Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?
Marwa Abdel Hamid, Lorenz M. Pammer, Theresa Lentner, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 10, pp. 1258-1270
Open Access | Times Cited: 6
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
Szu-Aun Long, Amber M. Amparo, Grace Goodhart, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response
Peiyuan Yang, Yongchao Li
Investigational New Drugs (2025)
Closed Access
The Pharmacologic inhibition of KRAS mutants as a treatment for cancer: Therapeutic principles and clinical results
Stefan Kasper, Martin Sebastian
Deutsches Ärzteblatt international (2025)
Closed Access
Treatment options for KRAS G12C mutated metastatic colorectal cancer
Marián Liberko
Onkologie (2025) Vol. 19, Iss. 1, pp. 33-36
Closed Access
Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors
Ramesh R. Kale, Charudatt Samant, Krishnadas Nandakumar, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151688-151688
Closed Access
Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
Tuan Hoang, Erica S. Tsang
Journal of Gastrointestinal Cancer (2025) Vol. 56, Iss. 1
Closed Access
Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer
Andrew J. Pellatt, Deepak Bhamidipati, Vivek Subbiah
JCO Oncology Practice (2024) Vol. 20, Iss. 10, pp. 1289-1292
Closed Access | Times Cited: 3
Bio-inspired biorthogonal compartmental microparticles for tumor chemotherapy and photothermal therapy
Qingfei Zhang, Gaizhen Kuang, Li Wang, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer
Emily Harrold, Fergus Keane, Henry Walch, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 12, pp. 2672-2683
Open Access | Times Cited: 2
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm
Paolo Ciracì, Vittorio Studiale, Ada Taravella, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 2
KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer
Annie Xiao, Marwan Fakih
Clinical Colorectal Cancer (2024) Vol. 23, Iss. 3, pp. 199-206
Closed Access | Times Cited: 1
KRAS Exon 2 Mutations in Patients with Sporadic Colorectal Cancer: Prevalence Variations in Mexican and Latin American Populations
José Luis Venegas-Rodríguez, Jesús Arturo Hernández-Sandoval, Melva Gutiérrez‐Angulo, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2323-2323
Open Access | Times Cited: 1
The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategies
Haitao Wang, Rui Tang, Jiang Ling, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Colorectal Cancer Screening: Time to Spring Forward
Aasma Shaukat, Seth D. Crockett
The American Journal of Gastroenterology (2024) Vol. 119, Iss. 3, pp. 395-396
Closed Access | Times Cited: 1
Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer
Hirotaka Miyashita, David S. Hong
Journal of Cancer Immunology (2024) Vol. 6, Iss. 2, pp. 62-69
Open Access | Times Cited: 1
Emerging Tumor-Agnostic Molecular Targets
Dedipya Bhamidipati, Alison M. Schram
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 11, pp. 1544-1554
Closed Access | Times Cited: 1
Origin, development and therapy of colorectal cancer from the perspective of a biologist and an oncologist
Jiří Švec, Jakub Onhajzer, Vladimír Kořínek
Critical Reviews in Oncology/Hematology (2024) Vol. 204, pp. 104544-104544
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top